Table 4.

Prevalence of Current Urate-Lowering Therapy (ULT) Use among Gout Patients in the US, NHANES 2013–2014^*

	Prevalence, % (95% CI)	Gout Patients on urate-lowering therapy (in millions)
All	35.5 (25.9, 46.4)	3.28
Sex
Female	15.5 (9.3, 24.7)	0.40
Male	43.0 (31.5, 55.3)	2.86
Age
20–39	42.9 (13.2, 78.9)	0.27
40–59	33.1 (15.4, 57.3)	1.15
60–79	37.3 (27.6, 48.2)	1.62
≥ 80	31.1 (13.8, 55.9)	0.26
Race/ethnicity
Non-Hispanic White	35.0 (24.2, 47.6)	2.47
Non-Hispanic Black	26.5 (17.6, 37.9)	0.32
Hispanic	57.7 (38.7, 74.7)	0.35
Other	43.4 (17.3, 73.8)	0.18

^*Data are presented incorporating sample weights and adjusted for clusters and strata of the complex sample design of NHANES 2013–2014.